title: Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid.
abstract: OBJECTIVE
  To determine in an eligible Utah Medicaid population (1) medical and drug costs associated with treating uterine fibroids (UFs) and (2) the cost and incidence of hysterectomy complications.
  
  
  METHODS
  Medical and drug cost analyses were based on data from 897 premenopausal patients with UFs included in the Utah Medicaid database from 1996 to 2004. UF-related medical and pharmacy costs were determined from first diagnosis of UFs until a related procedure or until estimated menopause. Outcomes for patients treated with a procedure (hysterectomy, myomectomy, or embolization), medication, and watchful waiting (no procedure, no UF-related drug) were compared. When determining hysterectomy complication rates for the population of women in the Medicaid database, a total of 1,323 pre- or postmenopausal patients with UFs were included.
  
  
  RESULTS
  Overall, 20% of patients were treated with medication, 33% with a procedure, and 47% with watchful waiting. Mean total UF costs were: $11,996 (procedure), $2,703 (medication), and $2,118 (watchful waiting). Mean eligibility months were 8.8, 28.8, and 14.1, respectively. Costs/eligible month were: $1,358 (procedure), $151 (watchful waiting), and $94 (medication). The mean hysterectomy cost was $12,107.
  
  
  CONCLUSIONS
  Treatment for UFs is expensive with a mean cost of $5,504 per study patient. The highest costs are seen in patients receiving procedures, which can lead to complications; 15% in this study. Costs for watchful waiting are similar to costs in patients receiving UF-related drugs. Consideration should be given to using non-surgical therapies for the treatment of UFs before procedures are performed.
authors.affiliation: Department of Pharmacotherapy, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, 421 Wakara Way, Suite 208, Salt Lake City, UT 84108, USA. gary.oderda@pharm.utah.edu
authors.forename: Gary
authors.initials: G
authors.lastname: Oderda
authors.forename: Carl
authors.initials: C
authors.lastname: Asche
authors.forename: Kirtly Parker
authors.initials: KP
authors.lastname: Jones
authors.forename: Ray M
authors.initials: RM
authors.lastname: Merrill
authors.forename: James
authors.initials: J
authors.lastname: Spalding
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D003365:Costs and Cost Analysis; D004621:Embolization, Therapeutic / Q000191:economics; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects / Q000191:economics; D007889:Leiomyoma / Q000191:economics* / Q000628:therapy*; D008484:Medicaid / Q000191:economics; D008875:Middle Aged; D014589:Utah; D014594:Uterine Neoplasms / Q000191:economics* / Q000628:therapy*